- 38
- 14 302
Sygnature Discovery
Приєднався 18 жов 2017
Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation. With over 700 staff, including 540 scientists, delivering over 40 pre-clinical and 21 clinical compounds, with scientists named on over 160 patents. Partnering global pharma, biotech, and NFP organisations, focussing on oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, and fibrotic diseases.
Learn more, visit our wesbite: www.sygnaturediscovery.com
Learn more, visit our wesbite: www.sygnaturediscovery.com
SCANME - a humanized neuroinflammation in vitro platform from Sygnature Discovery
SCANME scales up human disease modeling to push the boundaries of treatment for life-changing neuroinflammation related conditions such as Alzheimer's disease.
With unmatched cellular quality and disease relevance, increase your confidence in clinical translation and make meaningful drug discovery and development decisions. Powered by axoCells™ - the leading choice for functionally relevant human iPSC-derived cells (or customer's preferred source).
With unmatched cellular quality and disease relevance, increase your confidence in clinical translation and make meaningful drug discovery and development decisions. Powered by axoCells™ - the leading choice for functionally relevant human iPSC-derived cells (or customer's preferred source).
Переглядів: 1 317
Відео
iPSCs in neuroscience drug discovery
Переглядів 9721 день тому
Could iPSCs be the breakthrough we need in neuroscience drug discovery? Replicating CNS disease in these cells allows us to screen drugs directly in the relevant cell type and also in cells derived from patients, increasing confidence in clinical translation. Continue watching our insights on neuroscience drug discovery from our VP of Neuroscience, Dr Naheed (MAX) Rohman Mirza.
Sygnature Discovery Integrated Drug Discovery CRO
Переглядів 973 місяці тому
Sygnature Discovery is a world-leading integrated drug discovery contract research organisation based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global pharma, biotech, and NFP o...
#MitochondriaUnlocked_Tatiana's conclusions on mitochondria in drug development
Переглядів 225 місяців тому
In our 5 part series, #MitochondriaUnlocked, Tatiana from our neuroscience team looks at real-world data for mitochondrial function that helps decision-makers develop drugs in the CNS diseases space. This conclusion summarises the learnings from over the past 5 weeks including why pharma and biotech are pursuing mitochondrial health and how we can measure it. To download all of Tatiana’s insigh...
#MitochondriaUnlocked_Measuring the dynamics and biogenesis in different models
Переглядів 435 місяців тому
In our 5 part series #MitochondriaUnlocked, Tatiana from our neuroscience team shares real-world data for mitochondrial function that helps decision-makers developing drugs in the CNS diseases space. Today, Tatiana looks at measuring the mitochondrial dynamics and biogenesis in different models (ex vivo and in vivo) and the relevance of such analysis. To download all of Tatiana’s insights from ...
#MitochondriaUnlocked_How kinetics experiments unveil the complexities of this organelle (Part 3/5)
Переглядів 185 місяців тому
In our 5 part series, #MitochondriaUnlocked, Dr Tatiana Rosenstock from our neuroscience team shares real-world data on mitochondrial function that will help decision-makers in the CNS diseases space. Today, Tatiana considers the key concerns for pharma and biotech establishing a pharmacological approach in relation to mitochondrial function. To download all of Tatiana’s insights from this seri...
#MitochondriaUnlocked_Benefits of measuring mitochondrial function-2 different approaches (Part 2/5)
Переглядів 135 місяців тому
In our 5 part series, #MitochondriaUnlockedTatiana from our neuroscience team shares real-world data on mitochondrial function that helps decision-makers developing drugs in the CNS diseases space. Today, discover how to measure, in in-vitro models, key and specific energy metabolites which are related to maintaining energy such as ATP, ADP, NADH, pyruvate and lactate. To download all of Tatian...
#MitochondriaUnlocked_ The pursuit of mitochondrial function for large pharma & biotech (Part 1/5)
Переглядів 295 місяців тому
In our 5 part series, #MitochondriaUnlocked Dr Tatiana Rosenstock from our neuroscience team shares real-world data on mitochondrial function that will help decision-makers in the CNS diseases space. Today, Tatiana considers the key concerns for pharma and biotech establishing a pharmacological approach in relation to mitochondrial function. To download all of Tatiana’s insights from this serie...
Insights from Sygnature Discovery's CEO - The CRO market
Переглядів 8911 місяців тому
The outsourcing market has evolved. Sygnature Discovery's model has always been about strategic collaboration, which is now more widely accepted.
Insights from Sygnature Discovery's CEO - Industry
Переглядів 4011 місяців тому
Over the last 20 years, the market has evolved to strategic collaboration. Individuals come to CROs to access scientific expertise.
Insights from Sygnature Discovery's CEO - Importance of integrated drug discovery
Переглядів 3711 місяців тому
Drug discovery is a multi-disciplinary challenge. Integrating stages of drug discovery adds value to programs and allows for seamless innovation.
Insights from Sygnature Discovery's CEO - The CEO's journey
Переглядів 2511 місяців тому
Dr Simon Hirst started Sygnature Discovery 20 years ago, set to address common issues in the space. Dr Hirt wanted the company to have the right culture to support innovation and experience of drug discovery.
Insights from Sygnature Discovery's CEO - Importance of location
Переглядів 3211 місяців тому
Sygnature Discovery is based in two sites; Nottingham and Alderley Park. Nottingham is our HQ, a key location and an integral part of the Sygnature story. Alderley Park is a hub of life science companies, with cutting-edge facilities and a talent pool to tap into. Hear more about how we integrate the different sites, sharing a culture and unifying our values and approach.
Insights from Sygnature Discovery's CEO - Our achievements
Переглядів 2611 місяців тому
Over the last 20 years, Sygnature Discovery has grown into a global company. Created to address the common challenges in drug discovery, Sygnature Discovery brings different services into one holistic offering, adding value to programmes.
Insights from Sygnature Discovery's CE0 - Significance of recent acquisitions
Переглядів 5011 місяців тому
Sygnature Discovery's aim is to continue to deliver better drug discovery programmes by expanding our services. Hear from Dr Simon Hirst, our CEO, as he shares his thoughts on the value that acquisitions bring to Sygnature’s customers.
Insights from Sygnature Discovery's CEO - Sygnature's targeted protein degradation platform
Переглядів 6111 місяців тому
Insights from Sygnature Discovery's CEO - Sygnature's targeted protein degradation platform
Insights from Sygnature Discovery's CEO - Find out more about Sygnature Discovery
Переглядів 5111 місяців тому
Insights from Sygnature Discovery's CEO - Find out more about Sygnature Discovery
ANewDiscovery - Becoming a cross-Atlantic CRO
Переглядів 71Рік тому
ANewDiscovery - Becoming a cross-Atlantic CRO
A New Discovery - Sygnature Discovery becomes a transatlantic CRO
Переглядів 101Рік тому
A New Discovery - Sygnature Discovery becomes a transatlantic CRO
Alderley Park Directors Series - Chemistry
Переглядів 101Рік тому
Alderley Park Directors Series - Chemistry
Alderley Park Directors Series - Translational Oncology
Переглядів 66Рік тому
Alderley Park Directors Series - Translational Oncology
Alderley Park Directors Series - Bioscience
Переглядів 176Рік тому
Alderley Park Directors Series - Bioscience
Insights from Sygnature Discovery's CEO - What makes Sygnature Discovery a great place to work?
Переглядів 179Рік тому
Insights from Sygnature Discovery's CEO - What makes Sygnature Discovery a great place to work?
Sygnature Discovery - Integrated Drug Discovery CRO
Переглядів 895Рік тому
Sygnature Discovery - Integrated Drug Discovery CRO
CHARMED_Fast, combinatorial degrader discovery (US)
Переглядів 64Рік тому
CHARMED_Fast, combinatorial degrader discovery (US)
CHARMED_Fast, combinatorial degrader discovery from Sygnature Discovery
Переглядів 372Рік тому
CHARMED_Fast, combinatorial degrader discovery from Sygnature Discovery
Oncology drug discovery - current trends and reflections from our team
Переглядів 1352 роки тому
Oncology drug discovery - current trends and reflections from our team
Increasing Productivity with Integrated Strategies
Переглядів 2012 роки тому
Increasing Productivity with Integrated Strategies
Very insightful
🙈 Promo-SM!!
Amazing!!!